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Abciximab Coating Reduces Stent Restenosis
Abciximab is amonoclonal antibody that primarily targets the glycoprotein IIb/IIIareceptor, a key modifier of the platelet aggregation process. Recent studies have
shown that abciximab also has anti-inflammatory and anti-proliferative effects by cross
reacting with other receptors. Kim and colleagues hypothesized that coating a stent
with abciximabwould reduce the likelihoodof both stent thrombosis and restenosis. In
this trial, approximately 100 subjects with acutemyocardial infarction referred for PCI
were randomized to either a bare-metal stent or a stent coated with abciximab. The
abciximab-coated stent resulted in an approximately 50% reduction in late lumen loss
and binary restenosis rates. This preliminary trial suggests that abciximab-coated stents
are more effective than bare-metal stents in preventing restenosis and possibly throm-
bosis. See page 933.
Page 972
Coronary Artery Disease
LV Geometry Improves After Revascularization
The inciting factors for dysfunctional cardiac remodeling are poorly understood.Carluccio and colleagues hypothesized that the altered ventricular geometry in
patients with dysfunctional segmentsmay create a viscous cycle whereby increasedwall
stress leads to increased myocardial ischemia and worsening wall function. They used
echocardiography tomeasure several geometric factors of left ventricular (LV) function
in patients with ischemic but viable myocardium before and eight months after
revascularization.With revascularization, therewere improvements in ejection fraction
andwallmotion score index thatwere associatedwith improvements in volume indices
and sphericity index. The authors conclude that hibernatingmyocardium is associated
with major alterations in LV volumes and shape, and that chronic dyssynergy is
sufficient to induce LV remodeling. See page 969. See Figure.
Coronary Artery Disease
Mental Stress May Provoke Ischemia When Exercise Does Not
Acutemyocardial infarctions have been associatedwith increasedmental stress, andmany patients report typical angina during periods of increased stress. Although
previous studies have shown that mental stress can provoke ischemia in patients with
exercise-inducible ischemia, Ramachandruni and colleagues provokedmental stress in
patients with known coronary artery disease but recent negative exercise or chemical
stress tests. Emotional stress was induced in the subjects by charging them with a
difficult public speaking task; 99mTc-sestamibi was injected during the speech.
Twenty-nine percent of the patients had evidence of inducible ischemia (summed
difference score3).Whethermental stress provokes ischemia throughhemodynamic
changes or through endothelial vasoconstriction will require further study, but this
study confirms that mental stress can provoke angina even with a negative exercise or
pharmacologic stress test. See page 987.
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Atherosclerosis
Minimal Changes in Lumen Size May
Mask Large Reductions in Plaque Burden
Fornearly 20 years, it has been known that the coronary arteries enlarge tomaintainlumen size despite the accumulation of atherosclerotic plaque. Whether they will
shrink as the plaque shrinks is not known. Recently, apolipoprotein A-I Milano has
been shown to induce a small change in atheroma volume but not lumen size. In this
article, Nicholls and colleagues used intravascular ultrasound measurements to com-
pare changes in size of the various components of the arterial segments. They report
that a reduction in the atheroma volume of a segment is not associatedwith a change in
the luminal volume, rather the entire artery shrinks such that the luminal volume
remains constant. This reverse remodeling is most pronounced in the segments that
have lost the greatest amount of atheroma. This suggests that measuring changes in
luminal diameter will underestimate the effectiveness of interventions designed to
promote the regression of atherosclerosis. Instead, direct measurements of the amount
of plaque will be needed. See page 992. See figure.
Page 1015
Valvular Heart Disease
Early Surgery Better for Subjects With Severe Aortic Regurgitation
Current guidelines recommend valve replacement surgery for severe aortic regur-gitation (AR) once symptoms develop or there is evidence of either left ventric-
ular dilation (LVD) (end-systolic diameter [ESD]50 to 55mm) or reduced ejection
fraction (EF50%). These guidelines were based on previous studies suggesting that
patients with reduced EF or LVDwere likely to develop symptoms over the next year
and that symptomatic patients have worse perioperative mortality. Tornos and col-
leagues studied the outcomes of 170 patients with severe AR who underwent aortic
valve replacement at their institution; they stratified patients based on whether or not
they were operated on soon after theymet the previouslymentioned criteria or surgery
was delayeduntil theEFwas45%, theESDwas55mm,or the patientwas inNew
York Heart Association functional class III or IV. Patients operated on early after
fulfilling one of the indications had much better long-term outcomes; they were
approximately three times less likely to die of any cause and 10 times less likely to die of
congestive heart failure or sudden cardiac death. This study validates guidelines that
recommend that surgery should not be delayed once the EF has fallen below 50% or
the ESD has enlarged to50 mm. See page 1012. See figure.
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Echocardiography
Left Atrial Volume Predicts Future Cardiovascular Risk
Twoarticles in this issue assess the utility of the left atrium (LA) to serve as a generalcardiac risk stratifier. Tsang and colleagues used three different techniques to
measure the size of the LA in over 400patients and correlated thesemeasurementswith
clinical cardiovascular (CV) events over the next three years. They report that the left
atrial volume index (LAVI) is a more robust risk stratifier than either planimetered LA
area orM-mode–acquired LA dimension. They postulate that this is because the LA is
an asymmetrical structure thatmay dilate in different dimensions. In the second study,
Alsaileek and colleagues calculated the LAVI in 200 patients who underwent stress
echocardiography testing. They found that a normal LAVI (28 ml/m2) had a 95%
positive predictive value for a normal stress test. There was also a graded increase in the
likelihood of an abnormal test as the LAVI increased. Both of these articles suggest that
LAVI is robust maker of future cardiac risk. See pages 1018 and 1024. See
figure.
Hypertrophic Cardiomyopathy
Reduced Myocardial Blood Flow in HCM Patients
Hypertrophic cardiomyopathy (HCM) is a heterogeneous disorder in which aminority of patients develop left ventricular dilatation (LVD) and systolic
impairment. Olivotto and colleagues hypothesized that there was reduced blood flow
to the endocardium in patients who progressed to LVD. They used nitrogen-13–
labeled ammonia and positron emission tomographic scanning tomeasuremyocardial
blood flow (MBF) in milliliters per minute per gram of cardiac tissue at rest and after
inducing coronary vasodilation with dipyridamole; they then followed the subjects
clinically for an average of eight years. ThemaximalMBF inHCMpatientswas almost
50% less than healthy control subjects. Patients with lower MBF were more likely to
progress to LVD, severe heart failure, and death. Myocardial blood flow appears to be
a reliable indicator of the likelihood of disease progression in HCM and may become
an important method of risk stratification; whether reducedMBF is a causative factor
or reflects the severity of HCM requires further study. See page 1043.
